US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Takara Bio, Inc.

7.30

0.0000

Volume:- -

Turnover:- -

Market Cap:879.03M

PE:89.84

High:7.30

Open:7.30

Low:7.30

Close:7.30

52wk High:7.30

52wk Low:5.00

Shares:120.42M

Float Shares:44.35M

Volume Ratio:- -

T/O Rate:- -

Dividend:0.11

Dividend Rate:1.51%

EPS(TTM):0.0813

EPS(LYR):0.0813

ROE:-6.80%

ROA:-0.53%

PB:1.34

PE(LYR):89.84

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Takara Bio, Inc.

Exchange:

PINK LIMITED

Establishment Date:

2002

Employees:

1779

Office Location:

7-4-38 Nojihigashi,Kusatsu,Shiga,Japan

Website:

- -

Zip Code:

525-0058

Phone:

- -

Fax:

- -

Introduction:

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TKBIF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TKBIF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TKBIF\",,,,,undefined,":{"symbol":"TKBIF","market":"US","secType":"STK","nameCN":"Takara Bio, Inc.","latestPrice":7.3,"timestamp":1771862880000,"preClose":7.3,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":44350498,"shares":120415600,"eps":0.081259,"marketStatus":"Trading","change":0,"latestTime":"02-23 11:08:00 EST Delay","open":7.3,"high":7.3,"low":7.3,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.081259,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"exchange":"PINK LIMITED","adjPreClose":7.3,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TKBIF\",,,,,undefined,":{"symbol":"TKBIF","floatShares":44350498,"roa":"-0.53%","roe":"-6.80%","lyrEps":0.081259,"shares":120415600,"dividePrice":0.110075,"high":7.3,"amplitude":0,"preClose":7.3,"low":7.3,"week52Low":5,"pbRate":"1.34","psRate":"3.07","week52High":7.3,"institutionHeld":0,"latestPrice":7.3,"eps":0.081259,"divideRate":0.015079,"volume":0,"delay":15,"ttmEps":0.081259,"open":7.3,"prevYearClose":23.2,"prevWeekClose":7.3,"prevMonthClose":5,"prevQuarterClose":23.2,"fiveDayClose":5,"twentyDayClose":5,"sixtyDayClose":23.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TKBIF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-22","symbol":"TKBIF","reason":null,"defaultRemindTime":1737556200000,"announcedDate":"2025-01-21","type":"delisting","dateTimestamp":1737522000000},{"date":"2024-05-14","symbol":"TKBIF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"","dateTimestamp":1715659200000,"actualEps":null},{"market":"US","date":"2023-01-04","symbol":"TKBIF","reason":null,"defaultRemindTime":1672842600000,"announcedDate":"2023-01-03","type":"delisting","dateTimestamp":1672808400000},{"date":"2022-11-10","symbol":"TKBIF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1668070800000,"name":null,"time":"Pre-Market","dateTimestamp":1668056400000,"actualEps":null},{"market":"US","date":"2022-03-30","symbol":"TKBIF","amount":30,"defaultRemindTime":1648647000000,"name":"Takara Bio, Inc.","recordDate":"2022-06-25","payableDate":"2022-03-31","currency":"JPY","type":"dividend","dateTimestamp":1648612800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TKBIF\",market:\"US\",,,undefined,":[{"executeDate":"2020-03-30","recordDate":"2020-03-31","paymentDate":"2020-06-24","value":8,"currency":"JPY"},{"executeDate":"2021-03-30","recordDate":"2021-03-31","paymentDate":"2021-06-24","value":14,"currency":"JPY"},{"executeDate":"2022-03-30","recordDate":"2022-03-31","paymentDate":"2022-06-25","value":30,"currency":"JPY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TKBIF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.6667,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":3,"updateTime":1741755600000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":3698924,"yearFounded":2002,"employeeNum":1779,"address":"7-4-38 Nojihigashi,Kusatsu,Shiga,Japan","zipCode":"525-0058"},"stockCompanyDetail":{"description":"Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.","exchange":"PINK LIMITED","name":"Takara Bio, Inc.","nameEN":"Takara Bio, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"TKBIF\",market:\"US\",,,undefined,":null}}